HOUGHTON, Michael,LANDI, Abdolamir,LOGAN, Michael,LAW, John L.,CHEN, Chao,HOCKMAN, Darren
申请号：
AU2019233861
公开号：
AU2019233861A1
申请日:
2019.03.14
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides； ii) an HCV E1 polypeptide； or iii) an HCV E2 polypeptide； b) a polypeptide (also referred to herein as a "T-cell epitope polypeptide" or an "HCV T-cell epitope polypeptide") comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2； and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.
